体外炎症性肠病 (IBD) 诊断市场细分(按产品)(检测/生物标志物和分析仪);按疾病类型(溃疡性结肠炎和克罗恩病);按疾病阶段(轻度、中度和重度);按测试类型(血液测试、粪便测试、抗体测试和活检);按患者人口统计(儿童、成人和老年人);由最终用户(医院、诊所、诊断实验室等);以及测试方法 – 2019-2028 年全球需求分析和机会展望。

  • 报告编号: 3414
  • 发布日期: Feb 08, 2023
  • 报告格式: PDF, PPT

 

Global In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market Catalog

  1. introduce
    1. Market Definition
    2. market segmentation
    3. product description
  2. Assumptions and Market Estimates Warning
  3. Research Methodology
    1. research process
    2. initial research
    3. Secondary Research
  4. Executive Summary - In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market
  5. Market dynamics analysis
    1. Growth drivers
    2. Market Trends
    3. Growth Opportunities
    4. limit
  6. Regulatory and standards landscape
  7. Impact of COVID-19 on the In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market
    1. Impact on the overall market
    2. Impact on demand
    3. Impact on consumption
    4. Impact on drug manufacturers
    5. Impact on supply and distribution
    6. Impact on major market players
    7. Impact on pricing
  8. Market impact analysis of the COVID-19 pandemic in 2020 (quarterly) (US$ million)
  9. Pricing Analysis
  10. End-user analysis
  11. Epidemiological analysis
  12. Competition structure
    1. Targeting the in vitro diagnostics market
    2. Market share analysis in 2020
  13. In vitro inflammatory bowel disease diagnostics market segmentation
    1. By Product
      1. Detection/biomarkers
      2. Analyzer
    2. By disease type
      1. Ulcerative colitis
      2. Crohn's disease
    3. By disease stage
      1. Moderate
      2. Ease
      3. serious
    4. By test type
      1. blood test
      2. Stool tests
      3. Antibody testing
      4. Biopsy
    5. By Patient Demographics
      1. Pediatrics
      2. Adults
      3. Geriatrics
    6. By End User
      1. Hospital
      2. Clinic
      3. Diagnostic laboratories
      4. others
    7. By test method
      1. Petition
      2. Enzyme-linked immunosorbent assay
      3. quickly
      4. others
    8. By Region
      1. North America, 2019-2028 (US$ million)
      2. Latin America, 2019-2028 (US$ million)
      3. Europe, 2019-2028 (US$ million)
      4. Asia Pacific, 2019-2028 (US$ million)
      5. Middle East and Africa, 2019-2028 (US$ million)
  14. North America, 2019-2028 (US$ million)
    1. Market leader in in vitro inflammatory bowel disease diagnostics
    2. Pricing Outlook (USD)
    3. Reimbursement and Payment Policies by Country
    4. End-user analysis
    5. Annual testing volume analysis
    6. Test method analysis
    7. Dealer Outlook
    8. Market value (million USD)
    9. market segmentation
    10. By Product
      1. Detection/biomarkers
      2. Analyzer
    11. By disease type
      1. Ulcerative colitis
      2. Crohn's disease
    12. By disease stage
      1. Moderate
      2. Ease
      3. serious
    13. By test type
      1. blood test
      2. Stool tests
      3. Antibody testing
      4. Biopsy
    14. By Patient Demographics
      1. Pediatrics
      2. Adults
      3. Geriatrics
    15. By End User
      1. Hospital
      2. Clinic
      3. Diagnostic laboratories
      4. others
    16. By test method
      1. Petition
      2. Enzyme-linked immunosorbent assay
      3. quickly
      4. others
    17. nation
      1. USA
      2. Canada
      3. Mexico
  15. Latin America, 2019-2028 (US$ million)
    1. Market value (million USD)
    2. market segmentation
      1. By Product
      2. By disease type
      3. By disease stage
      4. By test type
      5. By Patient Demographics
      6. By End User
      7. By test method
      8. By Country
        1. Brazil
        2. Argentina
        3. Colombia
        4. Rest of Latin America
  16. Europe, 2019-2028 (US$ million)
    1. Market value (million USD)
    2. market segmentation
      1. By Product
      2. By disease type
      3. By disease stage
      4. By test type
      5. By Patient Demographics
      6. By End User
      7. By test method
      8. By Country
        1. France
        2. Italy
        3. Spain
        4. Germany
        5. U.K.
        6. Russia
        7. Rest of Europe
  17. Asia Pacific, 2019-2028 (US$ million)
    1. Market value (million USD)
    2. market segmentation
      1. By Product
      2. By disease type
      3. By disease stage
      4. By test type
      5. By Patient Demographics
      6. By End User
      7. By test method
      8. By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. South Korea
        6. Indonesia
        7. Rest of Asia Pacific
  18. Middle East and Africa, 2019-2028 (US$ million)
    1. Market value (million USD)
    2. market segmentation
      1. By Product
      2. By disease type
      3. By disease stage
      4. By test type
      5. By Patient Demographics
      6. By End User
      7. By test method
      8. By Country
        1. South Africa
        2. Gulf Cooperation Council
        3. Nigeria
        4. Rest of the MEA

 

 

Global In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market Highlights 2019-2028

The global in vitro inflammatory bowel disease (IBD) market is expected to reach revenues of USD 2,391.64 million by the end of 2028, up from USD 1,640 million in 2019, at a CAGR of 5.4% during the forecast period, i.e., 2021 – 2028. The growth of the market is primarily attributed to the rising prevalence of inflammatory bowel diseases across the globe, resulting in the need for individuals to be diagnosed with the disease. According to the statistical report titled “Global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis from the Global Burden of Disease Study 2017,” the global prevalence of IBD was recorded at 6.8 million in 2017. Furthermore, the statistics also indicate that the age-standardized prevalence of the disease reached 84.3 per 100,000 people in 2017, compared to 79.5 per 100,000 people in 1990. Furthermore, the market is also expected to grow on the back of rising healthcare expenditure and increasing research activities in the field of gastrointestinal science.

In vitro Inflammatory Bowel Disease (IBD) Diagnostics Market Map

The global in vitro inflammatory bowel disease (IBD) market is also expected to grow owing to the growing concern over the increasing incidence of digestive diseases worldwide and the growing awareness among individuals to treat such diseases. According to the Institute for Health Metrics and Evaluation (IHME), the number of deaths due to digestive diseases worldwide increased from 726,331.36 in 2000 to 939,281 in 2019.

Deaths caused by digestive system diseases

Global In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market Regional Overview

In terms of region, the global in vitro inflammatory bowel disease (IBD) market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The North American market is expected to hold the highest market share throughout the forecast period, driven by the increasing prevalence of IBD among individuals in the region, followed by the presence of strong healthcare networks in countries such as the United States and the growing healthcare expenditure in the countries in the region. The market in the region had a revenue of USD 723.24 million in 2019 and is expected to reach USD 1,067.01 million by the end of 2028. The market in the region is expected to grow at the highest CAGR of 5.7% during the forecast period.

On the other hand, the European market is expected to hold the second largest market share with revenues reaching $915.66 million by the end of 2028. Among the countries in the region, the German market is expected to occupy the second position - with revenues reaching $165.08 million by the end of 2028, up from $110.09 million in 2019.

The study further included North America (United States, Canada, Mexico), South America, Europe (UK, Germany, France, Italy, Spain, Hungary, Benelux [Belgium, Netherlands, Luxembourg], Nordics [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Growth drivers and challenges impacting the growth of the global in vitro inflammatory bowel disease (IBD) diagnostics market

Growth drivers

  • Increasing prevalence of IBD
  • Rapid research and development in gastrointestinal science

challenge

  • Strict product approval process

Global In Vitro Inflammatory Bowel Disease (IBD) Diagnostics Market Segment Overview

The global in vitro inflammatory bowel disease (IBD) diagnostics market is segmented by product into tests/biomarkers and analyzers. Of these, the tests/biomarkers segment is expected to hold the highest market share throughout the forecast period. This segment is expected to grow at the highest CAGR of 5.6% during the forecast period. Furthermore, based on disease type, the market is segmented into ulcerative colitis and Crohn's disease, of which ulcerative colitis is expected to hold the highest market share and grow at the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, of which the severe segment is expected to have the largest market revenue of $1,225.89 million by the end of 2028, up from $823.27 million in revenue in 2019. Furthermore, based on test type, the market is segmented into blood tests, stool tests, antibody tests, and biopsies. Among these segments, the blood test segment is expected to hold the highest market share and also reach a market revenue of $931.51 million by the end of 2028. Based on patient demographics, the market is segmented into pediatric, adult, and child. In the field of geriatrics, the adult market is expected to have the largest revenue of $1,592.15 million by the end of 2028. The market is also segmented based on end-user into hospitals, clinics, diagnostic laboratories, and others. Among these segments, the hospital segment is expected to hold the highest market share and also have a revenue of $1,297.52 million by the end of 2028. In addition, based on the test method, the market is segmented into PETIA, ELISA, and rapid, among which the ELISA segment is expected to have the highest market revenue of $663.62 million by the end of 2028, up from $428.08 million in 2019.

Top featured companies dominating the market

Our report covers detailed company profiles including company overview, business strategies, key products, financial performance, key performance indicators, risk analysis, latest developments, regional distribution and SWOT analysis, and other important competitive positioning indicators. Some of the prominent industry leaders in the global in vitro inflammatory bowel disease (IBD) market included in our report include DiaSorin SpA, American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, SL, BUHLMANN Laboratories AG, BioSystems SA, Inova Diagnostics, Inc. (Werfen), and others.

Top Reasons to Buy Our Reports

  • The report covers a detailed analysis of the market share gained by each segment and its sub-segments.
  • It covers the market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges impacting the market growth.
  • The report includes detailed company profiles of the key players dominating the market.
  • We use effective research methodologies to calculate market data and provide value-added assessments for overall growth.
  • We provide customized reports as per our clients’ requirements, helping them to see possible and unexpected challenges as well as unforeseen opportunities to help them achieve their goals.


In-the-news

在新闻中

 

  • July 12, 2021: Quidel announced that two of its products have received CE marking, the Savanna Multiplex Molecular Analyzer and the Savanna RVP4 Assay (Respiratory Virus Panel-4). The Savanna system is an automated in vitro diagnostic platform that is now available for sale in Europe and other countries that accept the CE mark.

 

作者学分:  Radhika Pawar


  • 报告编号: 3414
  • 发布日期: Feb 08, 2023
  • 报告格式: PDF, PPT

常見問題 (FAQ)

IBD 的日益流行是预计推动市场增长的主要因素之一。

在预测期内,即2021-2028年,市场预计复合年增长率为5.4%。

严格的产品审批规范是估计阻碍市场增长的主要因素之一。

预计欧洲市场在预测期内将呈现显着的增长机会。

市场上的主要参与者有 DiaSorin SpA、American Laboratory Products Company, Ltd.(d/b/a ALPCO Diagnostics)、Quidel Corporation、CerTest Biotec、SL、BUHLMANN Laboratories AG 等。

公司概况的选择基于产品领域产生的收入、公司的地理分布(决定创收能力)以及公司向市场推出的新产品。

市场按产品、疾病类型、疾病阶段、测试类型、患者人口统计、最终用户、测试方法和地区进行细分。

预计到 2028 年底,ELISA 细分市场将拥有 6.6362 亿美元的最大市场规模,并在未来几年展现出巨大的增长机会。
購買前詢問 索取免費樣品

  获取免费样品

免费样本副本包括市场概述、增长趋势、统计图表和表格、预测估计等等。

 索取免费样品副本

订购此报告之前如有疑问 ?

购买前询问